open access

Vol 28, No 1 (2021)
Technology Note
Published online: 2020-12-01
Submitted: 2020-11-22
Accepted: 2020-11-24
Get Citation

First-in-human radiofrequency ablation of ventricular tachycardia performed through an Atrial Flow Regulator device

Mateusz Wilkowski1, Łukasz Lewicki23, Rafał Olszewski1, Adam Priebe3, Miłosz J. Jaguszewski2, Marek Szołkiewicz3
DOI: 10.5603/CJ.a2020.0172
·
Pubmed: 33346370
·
Cardiol J 2021;28(1):161-162.
Affiliations
  1. St. Wojciech Hospital COPERNICUS, PL Gdansk, Poland, Długie Ogrody, Gdansk, Poland
  2. Medical University of Gdansk, Skłodowskiej-Curie 3a, 80-210 Gdansk, Poland
  3. Department of Cardiology and Angiology, Kashubian Center for Heart and Vascular Diseases, Pomeranian Hospitals, Wejherowo, Poland

open access

Vol 28, No 1 (2021)
Technology note — Interventional cardiology
Early publication date: 2020-12-01
Published online: 2020-12-01
Submitted: 2020-11-22
Accepted: 2020-11-24

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

First-in-human radiofrequency ablation of ventricular tachycardia performed through an Atrial Flow Regulator device

Journal

Cardiology Journal

Issue

Vol 28, No 1 (2021)

Article type

Technology Note

Pages

161-162

Early publication date

2020-12-01

Published online

2020-12-01

DOI

10.5603/CJ.a2020.0172

Pubmed

33346370

Bibliographic record

Cardiol J 2021;28(1):161-162.

Authors

Mateusz Wilkowski
Łukasz Lewicki
Rafał Olszewski
Adam Priebe
Miłosz J. Jaguszewski
Marek Szołkiewicz

References (3)
  1. Muser D, Liang JJ, Santangeli P. Electrical storm in patients with implantable cardioverter-defibrillators: a practical overview. J Innov Card Rhythm Manag. 2017; 8(10): 2853–2861.
  2. Lewicki Ł, Sabiniewicz R, Siebert J, et al. Atrial flow regulator as a novel therapy for patients with chronic heart failure. Cardiol J. 2020; 27(3): 309–311.
  3. Paitazoglou C, Özdemir R, Pfister R, et al. The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction. EuroIntervention. 2019; 15(5): 403–410.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl